Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis
Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis
复制标题
DOI：
10.1016/j.parkreldis.2008.07.004
复制
发表时间：
2009-05-01
影响因子：
4.1
通讯作者：
Coleman, Craig I.
中科院分区：
文献类型：
--
作者：
Baker, William L.;Silver, Dee;Coleman, Craig I.
我们的目的是对多巴胺激动剂（DA）作为早期治疗帕金森病（PD）的单一疗法和辅助疗法的随机对照试验进行荟萃分析。在2007年4月之前进行了系统的文献检索。对疗效和安全性终点进行了评估。与安慰剂相比，DA单药治疗的疗效更好，但不良事件发生率更高。此外，DA的疗效不如左旋多巴，但运动并发症较少。然而，da与更严重的副作用有关，如幻觉、嗜睡和头晕。DA是治疗早期PD的一种有效的治疗选择，尤其适用于左旋多巴后出现磨损现象或运动障碍的PD患者；然而，它可能导致更多的不良事件和更高的停药率。(C) 2008 Elsevier Ltd版权所有。
Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD). A systematic literature search was conducted through April 2007. Both efficacy and safety endpoints were evaluated. DA monotherapy showed superior efficacy but more frequent adverse events compared to placebo. In addition, DA demonstrated inferior efficacy to levodopa, but was associated with fewer motor complications. However, DAs were associated with a greater incidence of nuisance side effects, such as hallucinations, somnolence and dizziness. The use of DA is an effective treatment option for the treatment of early PD and appears especially useful among PD patients with wearing-off phenomenon or dyskinesias on levodopa; however it may result in more adverse events and higher withdrawal rates. (C) 2008 Elsevier Ltd. All rights reserved.